Accueil > La Médiathèque > International > CHINE > Les biotechnologies en Chine > Références

Enregistrer au format PDF

Les biotechnologies en Chine

Références

[1] Peter KARLSON. Biochimie. Douin. 1964.

[2] European life sciences ‘98 : continental shift ; the fifth annual Ernst & Young report on the European Entrepreneurial Life Sciences Industry.

[3] Integration. Ernst & Young’s Eighth Annual European Life Sciences Report 2001.

[4] Jikun HUANG, Scott ROZELLE, Carl PRAY, Qinfang WANG. Plant Biotechnology in China. Science Vol. 295, No. 5555 (Jan. 25, 2002), pp. 674-677. DOI : 10.1126/science.1067226

[5] Brevet sur le vivant : enjeux pour la santé. INSERM. Juillet 2002.

[6] Jean-Paul GAUDILLIERE. Entre biologistes, militaires et industriels : l’introduction de la pénicilline en France à la Libération. La revue pour l’histoire du CNRS 7

[7] Dilek DEMIRBAS. The EU Regulation on GMOs, Multinational Biotechnology Companies and their lobby group, EuropaBio. Eubios Journal of Asian and International Bioethics 13 (2003), 11-15.

[8] L’industrie des biotechnologies : contraintes et opportunités. In Dossier Biotechnologies. IHEST. Octobre 2003.

[9] Zhaohui PENG. The Genesis of Gendicine : The Story Behind the First Gene Therapy. BioPharm International. 1 May 2004.

[10] Sue PEARSON, Hepeng JIA, Keiko KANDACHI. China approves first gene therapy. Nature Biotechnology 2004, 22 ; 3 – 4. doi:10.1038/nbt0104-3

[11] Isabelle DEBRIX, Thierry ANDRÉ, Antoine FLAHAULT, Ogbe KALU, Joseph GLIGOROV, Jean-Pierre LOTZ, Bernard MILLERON, Françoise PENE, Yasmine BOUKARI, Annie BECKER. Evaluation du bon usage des anticancéreux : les limites des indications AMM. Bulletin du cancer 2004 ; 91 (5) : 437-43

[12] Can HUANG, Celeste AMORIM, Mark SPINOGLIO, Borges GOUVEIA, Augusto MEDINA. Organization, program and structure : an analysis of the Chinese innovation policy framework. R&D Management Volume 34, Issue 4, pages 367–387, September 2004.

[13] Jikun HUANG, Ruifa HU, Scott ROZELLE, Carl PRAY. Development, Policy and Impacts of Genetically Modified Crops in China : A Comprehensive Review of China’s Agricultural Biotechnology Sector. June 2005.

[14] Véronique DELCEY, Karine CHAMPION, Jean-François BERGMANN.
Maladies orphelines : évaluation et enregistrement des nouvelles thérapeutiques. Médecine/Sciences 2005 ; 21 (n° spécial) : 69-72

[15] LUO Gaoxing, WU Jun, CHEN Xiwei, HE WeiFeng, YI Shaoxuan, XIE Zhijie, ZHENG Junshong, ZHU Jin. CTLA4Ig Introduced by Adenovirus Vector Locally to Prolong the Survival of Xenogeneic Skin Grafts on Rat Burn Wounds. Journal of Trauma-Injury Infection & Critical Care 2005 59(5):1209-1215.

[16] Biotechnologies, brevets et agriculture : une nouvelle donne ? In Dossier Biotechnologies. IHEST. Novembre 2005.

[17] Synthèse de la mission d’étude en Caroline du Nord et à Philadelphie. Les entreprises du médicament – LEEM. 29 novembre 2005.

[18] Cellules souches et clonage : l’humain, un cas à part ? In Dossier Biotechnologies. IHEST. Juin 2006.

[19] Regenerative Medicine. Department of Health and Human Services. National Institutes of Health. August 2006.

[20] Yibing ZHOU. Contract Research Drives China’s Pharma Sector. PharmaManufacturing.com. August 2006.

[21] Xianwen HU, Qingjun MA, Shuyong ZHANG. Biopharmaceuticals in China. Biotechnology Journal 2006, 1, 1215–1224 DOI 10.1002/biot.200600083

[22] Chinese Biogenerics and Protection of IP, Large Market Potential and Solid Foundation Set the Stage. Genetic Engineering & Biotechnology News. Sep 1, 2006 (Vol. 26, No. 15).

[23] WANG Qian. What Kinds of Overseas Talents Does China Need ? 22 January 2007. www.china.org.cn/english/education/196881.htm

[24] Walters LEROY. Human Embryonic Stem Cell Research An Intercultural Perspective. University of Minnesota. 26 February 2007.

[25] Mark R. TRUSHEIM, Ernst R. BERNDT, Frank L. DOUGLAS. Stratified medicine : strategic and economic implications of combining drugs and clinical biomarkers. Nature Reviews Drug Discovery 6, 287-293 (April 2007) doi:10.1038/nrd2251.

[26] Eric LANGER. Biogenerics in China : An Evolving Industry. BioPharm International. 1 June 2007.

[27] Janet WOODCOCK, Joseph GRIFFIN, Rachel BEHRMAN, Barry CHERNEY, Terrie CRESCENZI, Blair FRASER, Dena HIXON, Christopher JONECKIS, Steven KOZLOWSKI, Amy ROSENBERG, Lewis SCHRAGER, Emily SHACTER, Robert TEMPLE, Keith WEBBER, Helen WINKLE. The FDA’s assessment of follow-on protein products : a historical perspective. Nature Reviews Drug Discovery 6, 437-442 (June 2007) | doi:10.1038/nrd2307

[28] Tomas JONSSON. Competitiveness of the European biotechnology industry. Commission européenne. 12 juillet 2007.

[29] Maurice CATIN et Christophe VAN HUFFEL. Clusters et stratégies de développement en Chine. LEAD, Université de Toulon. 2007.

[30] Xielin LIU, Nannan LUNDIN. Globalisation of the Biomedical Industry and the Biomedical Innovation System of China. SNS Project New Dynamics in the Swedish Innovation System. 2007.

[31] Michael L. EDELSTEIN, Mohammad R. ABEDI, Jo WIXON. Gene therapy clinical trials worldwide to 2007 – an update. The Journal of Gene Medicine 2007 ; 9 : 833–842. DOI : 10.1002/jgm.1100

[32] Yinliang LIU. Regulating transgenic technology in China : Law, regulation, and public policy. Economic and Social Research Council Genomics Network. 3 December 2007.

[33] Healthcare in China – poised for rapid growth. Goldman Sachs. 4 December 2007.

[34] Jean-Marie HURAUX. Virologie. Université Pierre et Marie Curie. 5 février 2008.

[35] Susan WARD. Demographic factors in the Chinese health-care market. Nature Reviews Drug Discovery 7, 383 (May 2008) doi:10.1038/nrd2527.

[36] Maria SONG. Pharma industry faces an increasingly stringent but more innovation-friendly drug registration environment in China. WiCON Pharma China. 12 August 2008.

[37] Biotechnology Research Continues to Bolster Arsenal Against Disease with 633 Medicines in Development. Biotechnology Medicines in Development – 2008 Report. Pharmaceutical Research and Manufacturers of America. 2008.

[38] Sarah E FREW, Stephen M SAMMUT, Alysha F SHORE, Joshua K RAMJIST, Sara AL-BADER, Rahim REZAIE, Abdallah S DAAR, Peter A SINGER. Chinese health biotech and the billion-patient market. Nature Biotechnology 26, 37 - 53 (2008) doi:10.1038/nbt0108-37.

[39] Gaspar TARONCHER-OLDENBURG, Andrew MARSHAL. Trends in biotech literature 2007. Nature Biotechnology 26, 1062 (2008). doi:10.1038/nbt1008-1062

[40] Guangyu MA, Hideaki SHIMADA, Kenzo HIROSHIMA, Yuji TADA, Nobuo SUZUKI, Masatoshi TAGAWA. Gene medicine for cancer treatment : Commercially available medicine and accumulated clinical data in China. Drug Design, Development and Therapy. 2008.

[41] Special Conference Reports. Trends in bio/pharmaceutical industry vol 4, n° 3, 2008.

[42] Lianming LIAO, Robert CHUNHUA ZHAO. An Overview of Stem Cell-Based Clinical Trials in China. Stem Cells and Development 17 (2008) 613-618. DOI : 10.1089/scd.2008.0183

[43] Zhu SHEN. Unleash the Dragon 2. PharmExec.com. 1 September 2008.

[44] Research Report on Chinese High-Tech Industries. U.S. China Economic and Security Review Commission. January 2009.

[45] Wei YUN. First Bio-Pharmaceutical Industrial Fund Established By Government in Shanghai. Medicine Economic News. 3 April 2009.

[46] HIV Infection – Guangdong Province. China, 1997-2007. CDC. 24 April 2009.

[47] Karolyn Y. ZENG. Stem Cell Therapy Today in the People’s Republic. h+ Magazine 28 April 2009.

[48] Jim ZHANG. China : Assessing the Need for Outsourcing. PharmaAsia. 1 mai 2009.

[49] Matthew CHERVENAK. Conducive factors aid China’s emergence in stem cells and regenerative medicine markets. Conference : ChinaBio Partnering Forum 2009. 6 May 2009.

[50] Market Report on China Biotechnology and Nanotechnology Industries. Italian Trade Commission, Shanghai Office. 18 June 2009.

[51] Pharmaceutical Sector Inquiry. Final Report. Commission européenne. 8 July 2009.
[52] Pharmaceutical Sector Inquiry. Final Report (Technical annex to the Commission Communication). Commission européenne. 8 July 2009.

[53] David CYRANOSKI. Stem-cell therapy faces more scrutiny in China. Nature 459, 146-147 (2009). doi:10.1038/459146a

[54] Investing in China’s Pharmaceutical Industry – 2nd Edition. PricewaterhouseCoopers. 2009.

[55] Judy XU, Yue YANG. Traditional Chinese medicine in the Chinese health care system. Health Policy 90 (2009) 133–139. doi:10.1016/j.healthpol.2008.09.003.

[56] Hervé THERY. Palmarès des universités mondiales, « Shanghai » et les autres. Maison de la Géographie de Montpellier. M@ppemonde 96 (4-2009).

[57] Jim J. ZHANG. Innovative Drug R&D in China. JZMed, Inc. October 2009.

[58] A Quick Overview of the Science and Technology System in China. swissnex Shanghai, October 2009.

[59] Création d’un fonds de finance à la demande de brevets dans les pays étrangers. Bulletins-électroniques.com. ADIT, Ambassade de France en Chine. 28 octobre 2009.

[60] China launches funds to back high-tech sectors. China Service Mall. 30 October 2009.

[61] James J. SHEN. China Pharmaceutical Guide 2009 (4th Edition). WiCON. 6 November 2009.

[62] Jiuding Capital Launches PE Fund for China Pharma. ChinaBio Today. 27 November 2009.

[63] China to give high-tech VC funds a hand. China Daily. 27 November 2009.

[64] Bernard MUNOS. Lessons from 60 years of pharmaceutical innovation. Nature Reviews Drug Discovery 8, 959-968 (December 2009) doi:10.1038/nrd2961.

[65] La nouvelle loi chinoise sur les brevets. Service Economique de l’Ambassade de France en Chine et Institut national de la propriété industrielle. 10 février 2010.

[66] Jean-Baptiste CHANIAL. La nouvelle loi chinoise sur les brevets et ses conséquences pour l’industrie pharmaceutique. BIOTECH FINANCES N° 451. 22 février 2010.

[67] Steven M. PAUL, Daniel S. MYTELKA, Christopher T. DUNWIDDIE, Charles C. PERSINGER, Bernard H. MUNOS, Stacy R. LINDBORG, Aaron L. SCHACHT. How to improve R&D productivity : the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery 9, 203-214 (March 2010) doi:10.1038/nrd3078.

[68] China Biotech Week in Review : CROs Consolidating. 2 May 2010.

[69] XiangCam – Chinese pharmaceutical company Xiangxue has set up its first overseas collaborative research centre in Cambridge to study traditional Chinese medicine. UK Trade & Investment. 24 May 2010.

[70] Evolving R&D for emerging markets. Nature Reviews Drug Discovery 9, 417-420 (June 2010) doi:10.1038/nrd3204.

[71] Changming LU. The first approved transgenic rice in China. GM Crops 1:3, 113-115 ; May/June 2010 © 2010 Landes Bioscience

[72] Salima HACEIN-BEY-ABINA, Julia HAUER, Annick LIM, Capucine PICARD, Gary P. WANG, Charles C. BERRY, Chantal MARTINACHE, Frédéric RIEUX-LAUCAT, Sylvain LATOUR, Bernd H. BELOHRADSKY, Lily LEIVA, Ricardo SORENSEN, Marianne DEBRÉ, Jean Laurent CASANOVA, Stephane BLANCHE, Anne DURANDY, Frederic D. BUSHMAN, Alain FISCHER, Marina CAVAZZANA-CALVO. Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency. The New England Journal of Medicine 363:355-364 July 22, 2010.

[73] Si-RMB PAN, Shan PAN, Zhi-Ling YU, Dik-Lung MA, Si-Bao CHEN, Wang-Fun FONG, Yi-Fan HAN, Kam-Ming KO. New Perspectives on Innovative Drug Discovery : An Overview. Journal of Pharmacy & Pharmaceutical Sciences 13(3) 450 - 471, 2010.

[74] Dominique S McMAHON, Halla THORSTEINSDÓTTIR, Peter A SINGER, Abdallah S DAAR. Cultivating regenerative medicine innovation in China. Regenerative Medicine (2010) 5(1), 35–44. doi:10.2217/RME.09.78

[75] Leonie C.M. KAPTEIN, Yuedan LI, Gerard WAGEMAKER. Gene Therapy in China - From a Dutch perspective. Netherlands Commission on Genetic Modification. 2010.

[76] Zhenggen HUANG, Junjie YANG, Gaoxing LUO, Chengjun GAN, Wenguang CHENG, Shunzong YUAN, Xu PENG, Jianglin TAN, Xiaojuan WANG, Jie HU, Shiwei YANG, Yair REISNER, Liangpeng GE, Hong WEI, Ping CHENG, Jun WU. Embryonic Porcine Skin Precursors Can Successfully Develop into Integrated Skin without Teratoma Formation Posttransplantation in Nude Mouse Model. PLoS ONE 2010 5(1) : e8717. doi:10.1371/journal.pone.0008717

[77] Xiaoyong ZHANG, Jikun HUANG, Huanguang QIU, Zhurong HUANG. A consumer segmentation study with regards to genetically modified food in urban China. Food Policy 35 (2010) 456–462. doi:10.1016/j.foodpol.2010.04.008

[78] Hepeng JIA. Chinese green light for GM rice and maize prompts outcry. Nature Biotechnology 28, 390–91 (2010) doi:10.1038/nbt0510-390b

[79] Hans De STEUR, Xavier GELLYNCK, Sergei STOROZHENKO, Ge LIQUN, Willy LAMBERT, Dominique Van Der STRAETEN, Jacques VIAENE. Health impact in China of folate-biofortified rice. Nature Biotechnology 28, 554–556 (2010) doi:10.1038/nbt0610-554

[80] Jamie K MILLER, Kent J BRADFORD. The regulatory bottleneck for biotech specialty crops. Nature Biotechnology 28, 1012–1014 (2010) doi:10.1038/nbt1010-1012

[81] Lindsay STAFFORD. Chinese Herbal Medicine Clears US FDA Phase II Trials. HerbalEGram Volume 7, Number 10, October 2010.

[82] Robert KNELLER. The importance of new companies for drug discovery : origins of a decade of new drugs. Nature Reviews Drug Discovery 9, 867-882 (November 2010) doi:10.1038/nrd3251

[83] La coopération scientifique et technologique franco-chinoise : le point de vue français. Stratégie nationale de recherche et d’innovation. Ministère de l’enseignement supérieur et de la recherche. Novembre 2010.

[84] Principales causes de décès (en %) en France (2008). IRDES. Janvier 2011.

[85] Joshua Emmanuel LAGOS, Wu BUGANG. Biotechnology – GE Plants and Animals. Annual 2010. Global Agricultural Information Network. USDA Foreign Agricultural Service. 28 January 2011.

[86] Jingzong QI, Qingli WANG, Zhenhang YU, Xin CHEN, Fengshan WANG. Innovative drug R&D in China. Nature Reviews Drug Discovery 10, 333-334 (May 2011). doi:10.1038/nrd3435.

[87] Nicolas LAROCHE, Pascale HENAUT, Pierre-Charles ROMOND. Culture, Migrants, and Risk Taking : The Case of the Biotechnology Sector in China. 56th annual ICSB World Conference. International Council for Small Business. Stockholm. 15-18 June 2011.

[88] Les biomédicaments. Les entreprises du médicament – LEEM. 5 mai 2011.

[89] Chiffre d’affaires. Les entreprises du médicament – LEEM. 21 juin 2011.

[90] Marché intérieur du médicament en France. Les entreprises du médicament – LEEM. 21 juin 2011.

[91] Guide to biotechnology 2008. Bio - Biotechnology Industry Organization. 16 August 2011.

[92] Inside the Cell. National Institute of General Medical Sciences. National Institutes of Health. 30 August 2011.

[93] Pharmaceuticals & Biotech Industry Global Report – 2011. IMAP.

[94] The Pharmaceutical Industry in Figures - Edition 2011. EFPIA European Federation of Pharmaceutical Industries and Associations. 2011.

[95] James CLIVE. Global Status of Commercialized Biotech/GM Crops : 2010. ISAAA Brief No. 42. ISAAA : Ithaca, New-York. 2011.

[96] Biotech Facts & Trends China. ISAAA : Ithaca, New-York. 2011.

[97] Nikolay TUROVETS, Andrey SEMECHKIN, Leonid KUZMICHEV, Jeffrey JANUS, Larissa AGAPOVA, Elena REVAZOVA. Derivation of Human Parthenogenetic Stem Cell Lines. In Human Pluripotent Stem Cells. Methods in Molecular Biology 2011, Volume 767, Part 2, 37-54, DOI : 10.1007/978-1-61779-201-4_4

[98] Hepeng JIA. Newsmaker : Biocentury Transgene. Nature Biotechnology 29, 12 (2011) doi:10.1038/nbt0111-12

[99] Wayne PENG. Trends in biotech literature 2009–2010. Nature Biotechnology. 29, 781 (8 September 2011). doi:10.1038/nbt.1971.

[100] Jin ZHU. Super rice yield sets world record. China Daily. 20 September 2011.

[101] 2011 EU Industrial R&D Investment Scoreboard. European Commission’s Joint Research Centre (JRC) - Institute for Prospective Technological Studies (IPTS), Directorate General for Research and Innovation, Directorate C. 18 October 2011. ISBN 978-92-79-21604-6.

[102] Haidan CHEN, Herbert GOTTWEIS. Stem cell treatments in China : rethinking the patient role in the global bio-economy. Bioethics 17 November 2011. DOI : 10.1111/j.1467-8519.2011.01929.x

[103] Alexey BERSENEV. The history of gene therapy drugs approval on the market. Stem Cell Assays. 21 December 2011.

[104] Décision d’exécution de la Commission du 22 décembre 2011 sur des mesures d’urgence concernant la présence non autorisée de riz génétiquement modifié dans les produits à base de riz provenant de Chine et abrogeant la décision 2008/289/CE (2011/884/UE). Commission européenne.

http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:343:0140:0148:FR:PDF

[105] Understanding Clinical Trials. ClinicalTrials.gov. National Institutes of Health.

[106] Query "gene therapy" OR "gene transfer" OR "virus delivery". ClinicalTrials.gov. National Institutes of Health. February 2012.

[107]Query "stem cells therapy" OR "regenerative medicine". ClinicalTrials.gov. National Institutes of Health. February 2012.

[108] Jin ZHU. Draft law on GM food online to solicit comments. China Daily. 23 February 2012.

[109] A propos de la réglementation des OGM en Chine et aux Etats-Unis. Mission d’animation des Agrobiosciences. 24 février 2012.

[110] Drug Administration Law of the People’s Republic of China. SFDA.

[111] Parcs scientifiques en Asie. UNESCO.

[112] Zhong-guan-cun (ZGC) Life Science Park.

[113] Comparatif : le droit à l’avortement dans les Etats membres. Toute l’Europe.

[114] University of Minnesota, World Stem cell Map.

lundi 21 septembre 2015, par HUCHERY Mélissa


Mots clés : Chine